EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Genetics Generation Advancement Corp. (4160) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Genetics Generation Advancement Corp. TWD 13.61, price TWD 39.45, upside -65.5%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW

GG Broad data Sep 24, 2026

Genetics Generation Advancement Corp.

4160 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 13.61 TWD · Strongly overvalued (−66%)
!Quality 37/100
!Expensive Growth (revenue 3y +3.3 %/yr)
!Thin margins · 2.9% net margin (TTM)
!negative free cash flow
!Trails peers (4/12)
!Narrow moat 22/100
!Weak on future: 19 out of 100
!Weak on past: 15 out of 100
Watch Genetics Generation Advancement Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

159.57 TWD 18.30 TWD Fair Value 13.61 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 18.30 TWD – 159.57 TWD · fair‑value band 10.21 TWD – 17.02 TWD · the 39.45 TWD price screens above the 13.61 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Genetics Generation Advancement in your weekly email

Every Wednesday you see whether Genetics Generation Advancement is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genetics Generation Advancement Corp. provides genetic testing, molecular and science diagnostics, biotechnology, precision health, and digital innovation services in Taiwan.

Show more

Genetics Generation Advancement Corp. provides genetic testing, molecular and science diagnostics, biotechnology, precision health, and digital innovation services in Taiwan. The company offers testing services, including pre-implantation, prenatal, newborn medical examination, health management, reproductive medicine testing, obstetrics and gynecology testing, and neonatology and pediatrics testing, as well as gastroenterology, hepatology, oncology, and medical research services. It also provides bioinformatic, materials sciences, research and development management, enterprise quality management, process production operation, and e-submission products. The company was formerly known as Genesis Genetics Asia Corp. and changed its name to Genetics Generation Advancement Corp. in February 2016. Genetics Generation Advancement Corp. was founded in 2008 and is based in Taipei City, Taiwan.

Stock analysis

Genetics Generation Advancement Corp. (4160) currently trades at 39.45 TWD, while our model-based Fair Value estimate is 13.61 TWD, implying the stock looks roughly 189.9% overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of 22.84 TWD per share, and 0 of the 16 models we run sit above the 39.45 TWD price.

Bear case: the Earnings-Based group reads lowest at 6.45 TWD, and 16 of the 16 models stay below the price. Evidence for this calculation is high.

Scenario range: 10.21 TWD (bear) to 17.02 TWD (bull), the price of 39.45 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Genetics Generation Advancement Corp. reported revenue of 603M TWD in FY2025 versus 520M TWD in FY2021, a compound +3.8%/yr. Reported net income was 21.4M TWD in FY2025, compounding +28.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap 1.1B TWD (≈ $33.1M) · P/E ratio 58.9 · P/S ratio 2.09 · EPS (TTM) 0.6700 TWD · Dividend yield 4.6% · Net margin 3.5% · Return on equity 3.7% · Return on assets (EBIT) 3.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −66%, 4160 screens richer than that median.

Fair Value models

Bear 10.21 TWD Fair Value 13.61 TWD Bull 17.02 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.4919 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income 16.50 TWD 16.36 TWD 14.34 TWD 73
Owner Earnings 8.41 TWD 10.70 TWD 13.75 TWD 72
EPV 5.91 TWD 6.45 TWD 6.92 TWD 68
All 16 models by family
DCF Models
Owner Earnings 8.41 TWD 10.70 TWD 13.75 TWD 72
Earnings-Based
Graham-Dodd 5.45 TWD 11.51 TWD 14.59 TWD 63
PEG = 1.0 1.74 TWD 2.48 TWD 3.23 TWD 55
EPV 5.91 TWD 6.45 TWD 6.92 TWD 68
Dividend Discount
Gordon GGM 16.22 TWD 24.11 TWD 32.19 TWD 66
DDM Multi-Stage 16.22 TWD 22.84 TWD 30.09 TWD 64
Multiples
P/E Multiple 12.61 TWD 16.82 TWD 21.02 TWD 63
P/S Multiple 10.21 TWD 13.61 TWD 17.02 TWD 58
P/B Multiple 10.21 TWD 13.61 TWD 17.02 TWD 55
EV/EBIT 8.58 TWD 10.61 TWD 12.65 TWD 63
EV/EBITDA 16.42 TWD 21.07 TWD 25.72 TWD 64
EV/Revenue 6.83 TWD 8.70 TWD 10.57 TWD 52
Asset-Based
NCAV (Graham) 11.27 TWD 15.10 TWD 22.54 TWD 51
Economic Profit
Residual Income 16.50 TWD 16.36 TWD 14.34 TWD 73
ROIC Compounder 5.91 TWD 6.45 TWD 6.92 TWD 67
Growth Earnings
Growth-Adj P/E 9.27 TWD 13.25 TWD 17.22 TWD 65

Open the full fair value analysis →

Notify me when 4160 reaches fair value

Put 4160 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 41 · Market factors (momentum, volatility) 30

Profitability 38
Margins and returns on capital today
Quality Growth 11
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 27
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.2%
Dividend (yield on the price)4.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 2%

4160 screens 190% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Genetics Generation Advancement Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −66% · Bottom 25%
Profitability
Return on equity (TTM) 4% · Above median
Return on assets 0% · Below median
Net margin (TTM) 3% · Below median
Operating margin (TTM) 0% · Below median
Growth and dividend
Revenue growth 4% · Below median
Dividend yield (TTM) 4.6% · Top 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 58.9× · Priciest 25%
P/B 1.76× · Cheaper than median
P/S (TTM) 1.73× · Cheaper than median
EV/EBITDA 48.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)19 · sector 25
PAST (return on equity)15 · sector 8
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)93 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $665.30 $682.58 +3%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genetics Generation Advancement Corp. · Fair Value
13.61 TWD −190%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Genetics Generation Advancement Corp. Fair Value". https://www.fairvalue-calculator.com/stock/4160

Frequently asked questions

Is Genetics Generation Advancement Corp. (4160) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 13.61 TWD versus a price of 39.45 TWD, about −66% upside (overvalued).
What is the fair value of 4160?
Our model-based fair value for Genetics Generation Advancement Corp. is 13.61 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 39.45 TWD.
What is the quality score of 4160?
Genetics Generation Advancement Corp. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genetics Generation Advancement Corp. (4160)?
Our model-based price target is the fair value of 13.61 TWD (as of Sep 24, 2026) from 16 valuation models. Cautious scenario 10.21 TWD, optimistic scenario 17.02 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Genetics Generation Advancement Corp. stock forecast for 2026?
Our models put fair value at 13.61 TWD, about −66% upside versus a price of 39.45 TWD (overvalued). Cautious scenario 10.21 TWD, optimistic scenario 17.02 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Genetics Generation Advancement Corp. (4160)?
Genetics Generation Advancement Corp. reported trailing-twelve-month revenue of about 614M TWD (latest available figure, as of Sep 24, 2026).
Does Genetics Generation Advancement Corp. pay a dividend?
Genetics Generation Advancement Corp. currently shows a dividend yield of about 4.65% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Genetics Generation Advancement Corp. (4160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genetics Generation Advancement Corp. it is 13.61 TWD per share (as of Sep 24, 2026), against a price of 39.45 TWD. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Genetics Generation Advancement Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4160 trades above its calculated fair value: price 39.45 TWD, fair value 13.61 TWD, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4160?
No. The price is what the market pays today (39.45 TWD); the fair value is what the company's own numbers justify (13.61 TWD). For Genetics Generation Advancement Corp. the two are 25.84 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Genetics Generation Advancement Corp. worth?
The market values Genetics Generation Advancement Corp. at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 39.45 TWD; our models calculate a fair value of 13.61 TWD per share.
What do the bullish and bearish scenarios say about 4160?
Our models span a range for Genetics Generation Advancement Corp.: cautious scenario 10.21 TWD, base 13.61 TWD, optimistic 17.02 TWD per share (as of Sep 24, 2026, price 39.45 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4160?
Genetics Generation Advancement Corp. trades at a price-to-earnings ratio of 58.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 13.61 TWD is built from several models across several years. Other multiples: P/B 1.8, P/S 1.7, EV/EBITDA 48.1.
How solid is the balance sheet of Genetics Generation Advancement Corp. (4160)?
Balance-sheet figures for Genetics Generation Advancement Corp. (as of Sep 24, 2026): return on equity 3.7%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 4160 from its 52-week high?
Genetics Generation Advancement Corp. trades at 39.45 TWD, about 75% below its 52-week high of 159.57 TWD and 7% above the low of 37.01 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 13.61 TWD is for.
Which stocks are comparable to Genetics Generation Advancement Corp.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genetics Generation Advancement Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price 39.45 TWD, calculated fair value 13.61 TWD (−66%), Quality Score 37/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4160 calculated?
We run Genetics Generation Advancement Corp. through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13.61 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Genetics Generation Advancement Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genetics Generation Advancement Corp. (4160)?
The closing price on Sep 24, 2026 was 39.45 TWD. Our model-based fair value is 13.61 TWD, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genetics Generation Advancement Corp. right now?
The price sits above even our optimistic bull case (17.02 TWD). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Genetics Generation Advancement Corp.

How large is the market capitalisation of Genetics Generation Advancement Corp. (4160)?
The market capitalisation of Genetics Generation Advancement Corp. is 1.1B TWD (≈ $33.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genetics Generation Advancement Corp. (4160)?
The price-to-sales ratio of Genetics Generation Advancement Corp. is 2.09 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genetics Generation Advancement Corp. (4160)?
Earnings per share at Genetics Generation Advancement Corp. are 0.6700 TWD (price ÷ EPS = P/E 58.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genetics Generation Advancement Corp. (4160)?
The dividend yield of Genetics Generation Advancement Corp. is 4.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genetics Generation Advancement Corp. (4160)?
The net margin of Genetics Generation Advancement Corp. is 3.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genetics Generation Advancement Corp. (4160)?
The return on equity (ROE) of Genetics Generation Advancement Corp. is 3.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genetics Generation Advancement Corp. (4160)?
On an EBIT basis the return on assets of Genetics Generation Advancement Corp. is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genetics Generation Advancement Corp. (4160)?
The operating margin of Genetics Generation Advancement Corp. is 0.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genetics Generation Advancement Corp. (4160)?
Revenue at Genetics Generation Advancement Corp. is growing +3.7% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genetics Generation Advancement Corp. (4160)?
Earnings per share at Genetics Generation Advancement Corp. are growing +188% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Genetics Generation Advancement Corp. (4160) generate?
The free cash flow of Genetics Generation Advancement Corp. is −49.6M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genetics Generation Advancement Corp. (4160) carry?
The net debt of Genetics Generation Advancement Corp. is 5.2M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genetics Generation Advancement Corp. in the live analysis

One click puts Genetics Generation Advancement Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.